AstraZeneca's shares rose 3% after the U.S. approved its lung cancer treatment Tagrisso for use with chemotherapy.

AstraZeneca's shares rose after the U.S. approved its lung cancer treatment Tagrisso. The approval was combined with chemotherapy, and the treatment reportedly slowed disease progression in patients with advanced lung cancer. AstraZeneca's shares jumped 3% to £103.96, and the company forecasts another year of double-digit growth.